Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model
John P Hanley, Huy A Tu, Julie A Dragon, Dorothy M Dickson, Roxana Del Rio-Guerra, Scott W Tighe, Korin M Eckstrom, Nicholas Selig, Samuel V Scarpino, Stephen S Whitehead, Anna P Durbin, Kristen K Pierce, Beth D Kirkpatrick, Donna M Rizzo, Seth Frietze, Sean A Diehl, John P Hanley, Huy A Tu, Julie A Dragon, Dorothy M Dickson, Roxana Del Rio-Guerra, Scott W Tighe, Korin M Eckstrom, Nicholas Selig, Samuel V Scarpino, Stephen S Whitehead, Anna P Durbin, Kristen K Pierce, Beth D Kirkpatrick, Donna M Rizzo, Seth Frietze, Sean A Diehl
Abstract
About 20-25% of dengue virus (DENV) infections become symptomatic ranging from self-limiting fever to shock. Immune gene expression changes during progression to severe dengue have been documented in hospitalized patients; however, baseline or kinetic information is difficult to standardize in natural infection. Here we profile the host immunotranscriptome response in humans before, during, and after infection with a partially attenuated rDEN2Δ30 challenge virus (ClinicalTrials.gov NCT02021968). Inflammatory genes including type I interferon and viral restriction pathways are induced during DENV2 viremia and return to baseline after viral clearance, while others including myeloid, migratory, humoral, and growth factor immune regulation factors pathways are found at non-baseline levels post-viremia. Furthermore, pre-infection baseline gene expression is useful to predict rDEN2Δ30-induced immune responses and the development of rash. Our results suggest a distinct immunological profile for mild rDEN2Δ30 infection and offer new potential biomarkers for characterizing primary DENV infection.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507. doi: 10.1038/nature12060.
- WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition.) World Health Organization (2009).
- Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393:350–363. doi: 10.1016/S0140-6736(18)32560-1.
- Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat. Rev. Dis. Prim. 2016;2:16055. doi: 10.1038/nrdp.2016.55.
- Brathwaite Dick, O. et al. The history of dengue outbreaks in the Americas. Am. J. Trop. Med. Hyg.87, 584–593 (2012).
- Gibbons RV, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg. 2007;77:910–913. doi: 10.4269/ajtmh.2007.77.910.
- Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007;5:518–528. doi: 10.1038/nrmicro1690.
- Katzelnick LC, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929–932. doi: 10.1126/science.aan6836.
- St John AL, Rathore APS. Adaptive immune responses to primary and secondary dengue virus infections. Nat. Rev. Immunol. 2019;19:218–230. doi: 10.1038/s41577-019-0123-x.
- Devignot S, et al. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. PLoS ONE. 2010;5:e11671. doi: 10.1371/journal.pone.0011671.
- Hoang LT, et al. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J. Virol. 2010;84:12982–12994. doi: 10.1128/JVI.01224-10.
- Kwissa M, et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe. 2014;16:115–127. doi: 10.1016/j.chom.2014.06.001.
- Loke P, et al. Gene expression patterns of dengue virus-infected children from nicaragua reveal a distinct signature of increased metabolism. PLoS Negl. Trop. Dis. 2010;4:e710. doi: 10.1371/journal.pntd.0000710.
- Long HT, et al. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J. Infect. Dis. 2009;199:537–546. doi: 10.1086/596507.
- Nascimento EJ, et al. Gene expression profiling during early acute febrile stage of dengue infection can predict the disease outcome. PLoS ONE. 2009;4:e7892. doi: 10.1371/journal.pone.0007892.
- Simmons CP, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 2007;195:1097–1107. doi: 10.1086/512162.
- Sun P, et al. Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity. PLoS Negl. Trop. Dis. 2013;7:e2298. doi: 10.1371/journal.pntd.0002298.
- van de Weg CA, et al. Time since onset of disease and individual clinical markers associate with transcriptional changes in uncomplicated dengue. PLoS Negl. Trop. Dis. 2015;9:e0003522. doi: 10.1371/journal.pntd.0003522.
- Zanini F, et al. Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue. Proc. Natl Acad. Sci. U.S.A. 2018;115:E12363–E12369. doi: 10.1073/pnas.1813819115.
- Robinson M, et al. A 20-gene set predictive of progression to severe dengue. Cell Rep. 2019;26:1104–1111.e1104. doi: 10.1016/j.celrep.2019.01.033.
- Clapham H, et al. Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics. PLoS Negl. Trop. Dis. 2015;9:e0004262. doi: 10.1371/journal.pntd.0004262.
- Durbin AP, Whitehead SS. The dengue human challenge model: has the time come to accept this challenge? J. Infect. Dis. 2013;207:697–699. doi: 10.1093/infdis/jis749.
- Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. Vaccine. 2015;33:7075–7082. doi: 10.1016/j.vaccine.2015.09.052.
- Mammen MP, et al. Evaluation of dengue virus strains for human challenge studies. Vaccine. 2014;32:1488–1494. doi: 10.1016/j.vaccine.2013.12.040.
- Gunther VJ, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine. 2011;29:3895–3904. doi: 10.1016/j.vaccine.2011.03.038.
- Gubler DJ, Reed D, Rosen L, Hitchcock JR., Jr. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am. J. Trop. Med. Hyg. 1978;27:581–589. doi: 10.4269/ajtmh.1978.27.581.
- Blaney JE, Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 2004;4:39. doi: 10.1186/1471-2334-4-39.
- Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011;29:7242–7250. doi: 10.1016/j.vaccine.2011.07.023.
- Kirkpatrick BD, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci. Transl. Med. 2016;8:330ra336. doi: 10.1126/scitranslmed.aaf1517.
- Grifoni A, et al. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Delta30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. J. Virol. 2017;91:e02133–02116.
- Halstead SB. Dengue. Lancet. 2007;370:1644–1652. doi: 10.1016/S0140-6736(07)61687-0.
- Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 2015;12:453–457. doi: 10.1038/nmeth.3337.
- Tran TM, et al. A molecular signature in blood reveals a role for p53 in regulating malaria-induced inflammation. Immunity. 2019;51:750–765.e710. doi: 10.1016/j.immuni.2019.08.009.
- Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HW. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood. 1996;87:373–377. doi: 10.1182/blood.V87.1.373.373.
- Angelo MA, et al. Human CD4(+) T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J. Virol. 2017;91:e02147–02116. doi: 10.1128/JVI.02147-16.
- Graham N, et al. Rapid induction and maintenance of virus-specific CD8(+) TEMRA and CD4(+) TEM cells following protective vaccination against dengue virus challenge in humans. Front Immunol. 2020;11:479. doi: 10.3389/fimmu.2020.00479.
- Weiskopf D, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol. 2015;89:120–128. doi: 10.1128/JVI.02129-14.
- Weiskopf D, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl Acad. Sci. U.S.A. 2013;110:E2046–E2053. doi: 10.1073/pnas.1305227110.
- Weiskopf D, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl Acad. Sci. U.S.A. 2015;112:E4256–E4263. doi: 10.1073/pnas.1505956112.
- Perng YC, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 2018;16:423–439. doi: 10.1038/s41579-018-0020-5.
- Nivarthi UK, et al. Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model. EBioMedicine. 2019;41:465–478. doi: 10.1016/j.ebiom.2019.02.060.
- Simmons JS, St John JH, Reynolds FHK. Numerical and morphological alterations of the leukocytes during dengue fever. Phillipine J. Sci. 1931;44:128–146.
- Unger G, Chor B. Linear separability of gene expression data sets. IEEE/ACM Trans. Comput Biol. Bioinform. 2010;7:375–381. doi: 10.1109/TCBB.2008.90.
- Popper SJ, et al. Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl. Trop. Dis. 2012;6:e1966. doi: 10.1371/journal.pntd.0001966.
- Vaughn DW, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000;181:2–9. doi: 10.1086/315215.
- Durbin AP, et al. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology. 2008;376:429–435. doi: 10.1016/j.virol.2008.03.028.
- Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front Immunol. 2014;5:647. doi: 10.3389/fimmu.2014.00647.
- Michlmayr D, Andrade P, Gonzalez K, Balmaseda A, Harris E. CD14(+)CD16(+) monocytes are the main target of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. Nat. Microbiol. 2017;2:1462–1470. doi: 10.1038/s41564-017-0035-0.
- Roth H, et al. Flavivirus infection uncouples translation suppression from cellular stress responses. mBio. 2017;8:e02150–16.
- Hishiki T, et al. Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication. Biochem. Biophys. Res. Commun. 2014;448:95–100. doi: 10.1016/j.bbrc.2014.04.081.
- Chan KR, et al. Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection. Nat. Med. 2019;25:1218–1224. doi: 10.1038/s41591-019-0510-7.
- Popper SJ, et al. Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers. J. Infect. Dis. 2018;218:1911–1921. doi: 10.1093/infdis/jiy434.
- Santos JC, Broz P. Sensing of invading pathogens by GBPs: at the crossroads between cell-autonomous and innate immunity. J. Leukoc. Biol. 2018;104:729–735. doi: 10.1002/JLB.4MR0118-038R.
- Durbin AP, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 2013;207:957–965. doi: 10.1093/infdis/jis936.
- Kirkpatrick BD, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 2015;212:702–710. doi: 10.1093/infdis/jiv082.
- Durbin AP, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 2005;191:710–718. doi: 10.1086/427780.
- Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat. Protoc. 2016;11:1650–1667. doi: 10.1038/nprot.2016.095.
- ENCODE. ENCODE experimental guidelines for ENCODE3 RNA-seq. (2017).
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616.
- McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40:4288–4297. doi: 10.1093/nar/gks042.
- Fu J., Frazee A. C., Collado-Torres L., Jaffe A. E., Leek J. T. ballgown: flexible, isoform-level differential expression analysis.). 2.18.0 edn. R package version (2019).
- Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43:W566–W570. doi: 10.1093/nar/gkv468.
- Li H, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–2079. doi: 10.1093/bioinformatics/btp352.
- Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930. doi: 10.1093/bioinformatics/btt656.
- Brodin P, Davis MM. Human immune system variation. Nat. Rev. Immunol. 2017;17:21–29. doi: 10.1038/nri.2016.125.
- Dalman MR, Deeter A, Nimishakavi G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinform. 2012;13(Suppl 2):S11. doi: 10.1186/1471-2105-13-S2-S11.
- Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211.
- Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199–W205. doi: 10.1093/nar/gkz401.
- Mi H, et al. Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0) Nat. Protoc. 2019;14:703–721. doi: 10.1038/s41596-019-0128-8.
- Moncunill G, Han H, Dobano C, McElrath MJ, De Rosa SC. OMIP-024: pan-leukocyte immunophenotypic characterization of PBMC subsets in human samples. Cytom. A. 2014;85:995–998. doi: 10.1002/cyto.a.22580.
- Dan JM, et al. A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4+ T cells in blood. J. Immunol. 2016;197:983–993. doi: 10.4049/jimmunol.1600318.
- Rydyznski Moderbacher C, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e1019. doi: 10.1016/j.cell.2020.09.038.
Source: PubMed